Sputnik V, a Russian coronavirus vaccine, has been registered in Nepal. This was reported on Tuesday, April 20, in Twitter– vaccine account.
It is clarified that Nepal became the 61st country in which the use of the drug was approved.
Earlier on the same day, the Russian Direct Investment Fund (RDIF) announced that Argentina was the first country in Latin America to begin production of the Sputnik V vaccine. It is added that the full-scale production of the Russian drug for coronavirus infection in Argentina will begin in June.
The day before, it was reported that the effectiveness of the Sputnik V vaccine was 97.6% according to the results of a study of data on 3.8 million vaccinated Russians. An update on the drug’s efficacy will be published in a peer-reviewed medical journal in May 2021, according to the developers.
At the same time, the director of the Gamaleya center that developed the drug, Alexander Gintsburg, indicated that the real effectiveness of the vaccine may be even higher than the declared indicators. RDIF CEO Kirill Dmitriev added that the results obtained during the analysis make Sputnik V one of the best drugs protecting against coronavirus among all vaccines in the world.
Sputnik V, the first COVID-19 vaccine in Russia and the world, was registered on August 11, 2020. At the moment, the drug is one of the three leaders in terms of the number of registrations in the countries of the world.